Key result
Bucindolol reduced mortality in heart failure patients with wild-type alpha(2C)-AR, but provided no survival benefit in alpha(2C) Del carriers.
Why the study?
Does the therapeutic response and norepinephrine-lowering effect of bucindolol vary by alpha(2C)-adrenergic receptor polymorphism in patients with chronic heart failure?
RCT (n=1,040)
randomized
Does the therapeutic response and norepinephrine-lowering effect of bucindolol vary by alpha(2C)-adrenergic receptor polymorphism in patients with chronic heart failure?
The survival benefit of bucindolol in chronic heart failure is strongly dependent on the alpha(2C)-adrenergic receptor genotype, with benefit restricted to wild-type carriers.
Answers are grounded in this paper and cite their sources.
May warrant alpha(2C)-AR genotyping before bucindolol; extends pharmacogenomic stratification of beta-blocker therapy in HF.
BACKGROUND: Adrenergic activation is an important determinant of outcomes in chronic heart failure. Adrenergic activity is regulated in part by prejunctional alpha(2C)-adrenergic receptors (ARs), which exhibit genetic variation in humans. Bucindolol is a novel beta-AR blocking agent that also lowers systemic norepinephrine and thus is also a sympatholytic agent. This study investigated whether alpha(2C)-AR polymorphisms affect sympatholytic effects of bucindolol in patients with heart failure. METHODS AND RESULTS: In the beta-Blocker Evaluation of Survival Trial, adrenergic activation was estimated by systemic venous norepinephrine measured at baseline, 3 months, and 12 months posttreatment in patients treated with placebo or bucindolol. In the beta-Blocker Evaluation of Survival Trial AR polymorphism substudy, DNA was collected from 1040 of the 2708 randomized patients, and alpha(2C)-AR gene polymorphisms (alpha(2C) Del322-325 or the wild-type counterpart) were measured by polymerase chain reaction and gel electrophoresis. Patients who were alpha(2C) Del carriers (heterozygotes or homozygotes) exhibited a much greater sympatholytic response to bucindolol (decrease in norepinephrine at 3 months of 153+/-57 pg/mL, P=0.012 compared with placebo versus decrease of 50+/-13 pg/mL in alpha(2C) wild type, P=0.0005 versus placebo; P=0.010 by interaction test). alpha(2C) Del carriers had no evidence of a favorable survival benefit from bucindolol (mortality compared with placebo hazard ratio, 1.09; 95% CI, 0.57 to 2.08; P=0.80), whereas bucindolol-treated subjects who were wild type for the alpha(2C)-AR had a 30% reduction in mortality (hazard ratio, 0.70; 95% CI, 0.51 to 0.96; P=0.025). CONCLUSIONS: In the beta-Blocker Evaluation of Survival Trial AR polymorphism substudy, the norepinephrine lowering and clinical therapeutic responses to bucindolol were strongly influenced by alpha(2C) receptor genotype.
No takes yet. Share an insight, caveat, or question.
Bristow et al. (2009) conducted an RCT in chronic heart failure (n=1,040). Bucindolol vs. Placebo was evaluated on Mortality in alpha(2C)-AR wild type patients (HR 0.70, 95% CI 0.51-0.96, p=0.025). Bucindolol reduced mortality in heart failure patients with wild-type alpha(2C)-AR, but provided no survival benefit in alpha(2C) Del carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: